{"id":44040,"date":"2025-10-22T19:38:23","date_gmt":"2025-10-22T11:38:23","guid":{"rendered":"https:\/\/flcube.com\/?p=44040"},"modified":"2025-10-22T19:38:23","modified_gmt":"2025-10-22T11:38:23","slug":"novartis-announces-five%e2%80%91year-natalee-results-for-kisqali-in-hr-her2%e2%80%91-early-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44040","title":{"rendered":"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer"},"content":{"rendered":"\n<p><strong>Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>)<\/strong> presented the five\u2011year interim analysis of its pivotal <strong>Phase\u202fIII NATALEE<\/strong> study at the <strong>2025 European Society for Medical Oncology (ESMO) Congress<\/strong>. The data demonstrate that patients receiving <strong>Kisqali (ribociclib)<\/strong> in combination with endocrine therapy (ET) continue to reap benefits nearly two\u202fyears after completing three\u202fyears of treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-findings\"><strong>Key Findings<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Extended Follow\u2011Up<\/strong> \u2013 Median follow\u2011up of <strong>58.4\u202fmonths<\/strong> confirms durable benefit.<\/li>\n\n\n\n<li><strong>Recurrence Reduction<\/strong> \u2013 In a broad cohort of <strong>high\u2011risk Stage\u202fII\/III HR+\/HER2\u2011<\/strong> early breast cancer (EBC) patients, <strong>Kisqali\u202f+\u202fET<\/strong> reduced the risk of recurrence by <strong>28.4\u202f%<\/strong> versus ET alone (HR\u202f=\u202f0.716; 95\u202f%\u202fCI\u202f0.618\u20110.829; P\u202f&lt;\u202f0.0001).<\/li>\n\n\n\n<li><strong>Broad Population Benefit<\/strong> \u2013 The benefit spans patients with diverse tumor biology and prior treatment histories.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-kisqali-ribociclib\"><strong>About Kisqali (Ribociclib)<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Selective CDK4\/6 Inhibitor<\/strong> \u2013 Targets cyclin\u2011dependent kinases 4 and 6, halting tumor cell cycle progression.<\/li>\n\n\n\n<li><strong>Global Approval<\/strong> \u2013 Licensed in <strong>>100 countries<\/strong> for breast cancer treatment.<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong> \u2013 Proven efficacy across metastatic, early\u2011stage, and adjuvant settings.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-implications-for-oncology-practice\"><strong>Implications for Oncology Practice<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Long\u2011Term Disease Control<\/strong> \u2013 Supports the role of prolonged CDK4\/6 inhibition in preventing recurrence.<\/li>\n\n\n\n<li><strong>Patient Management<\/strong> \u2013 Provides clinicians with evidence to justify extended therapy beyond the initial three\u2011year window.<\/li>\n\n\n\n<li><strong>Strategic Positioning<\/strong> \u2013 Strengthens Novartis\u2019s portfolio in the highly competitive HR+\/HER2\u2011 breast\u2011cancer market.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis (NYSE: NVS) presented the five\u2011year interim analysis of its pivotal Phase\u202fIII NATALEE study at&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44087,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,17,140,865],"class_list":["post-44040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-clinical-trial-results","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE: NVS) presented the five\u2011year interim analysis of its pivotal Phase\u202fIII NATALEE study at the 2025 European Society for Medical Oncology (ESMO) Congress. The data demonstrate that patients receiving Kisqali (ribociclib) in combination with endocrine therapy (ET) continue to reap benefits nearly two\u202fyears after completing three\u202fyears of treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44040\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE: NVS) presented the five\u2011year interim analysis of its pivotal Phase\u202fIII NATALEE study at the 2025 European Society for Medical Oncology (ESMO) Congress. The data demonstrate that patients receiving Kisqali (ribociclib) in combination with endocrine therapy (ET) continue to reap benefits nearly two\u202fyears after completing three\u202fyears of treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44040\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T11:38:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\\\/HER2\u2011 Early Breast Cancer\",\"datePublished\":\"2025-10-22T11:38:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040\"},\"wordCount\":236,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2201.webp\",\"keywords\":[\"Academic conference\",\"Cancer\",\"Clinical trial results\",\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44040#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44040\",\"name\":\"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\\\/HER2\u2011 Early Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2201.webp\",\"datePublished\":\"2025-10-22T11:38:23+00:00\",\"description\":\"Novartis (NYSE: NVS) presented the five\u2011year interim analysis of its pivotal Phase\u202fIII NATALEE study at the 2025 European Society for Medical Oncology (ESMO) Congress. The data demonstrate that patients receiving Kisqali (ribociclib) in combination with endocrine therapy (ET) continue to reap benefits nearly two\u202fyears after completing three\u202fyears of treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44040\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\\\/HER2\u2011 Early Breast Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44040#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\\\/HER2\u2011 Early Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis (NYSE: NVS) presented the five\u2011year interim analysis of its pivotal Phase\u202fIII NATALEE study at the 2025 European Society for Medical Oncology (ESMO) Congress. The data demonstrate that patients receiving Kisqali (ribociclib) in combination with endocrine therapy (ET) continue to reap benefits nearly two\u202fyears after completing three\u202fyears of treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44040","og_locale":"en_US","og_type":"article","og_title":"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer","og_description":"Novartis (NYSE: NVS) presented the five\u2011year interim analysis of its pivotal Phase\u202fIII NATALEE study at the 2025 European Society for Medical Oncology (ESMO) Congress. The data demonstrate that patients receiving Kisqali (ribociclib) in combination with endocrine therapy (ET) continue to reap benefits nearly two\u202fyears after completing three\u202fyears of treatment.","og_url":"https:\/\/flcube.com\/?p=44040","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-22T11:38:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44040#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44040"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer","datePublished":"2025-10-22T11:38:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44040"},"wordCount":236,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44040#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2201.webp","keywords":["Academic conference","Cancer","Clinical trial results","Novartis","NYSE: NVS"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44040#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44040","url":"https:\/\/flcube.com\/?p=44040","name":"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44040#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44040#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2201.webp","datePublished":"2025-10-22T11:38:23+00:00","description":"Novartis (NYSE: NVS) presented the five\u2011year interim analysis of its pivotal Phase\u202fIII NATALEE study at the 2025 European Society for Medical Oncology (ESMO) Congress. The data demonstrate that patients receiving Kisqali (ribociclib) in combination with endocrine therapy (ET) continue to reap benefits nearly two\u202fyears after completing three\u202fyears of treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44040#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44040"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44040#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2201.webp","width":1080,"height":608,"caption":"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44040#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Announces Five\u2011Year NATALEE Results for Kisqali in HR+\/HER2\u2011 Early Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2201.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44040"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44040\/revisions"}],"predecessor-version":[{"id":44088,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44040\/revisions\/44088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44087"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}